Real-world study for the safety of Apatinib Mesylate Tablets

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024531

Enrollment

Unknown

Registered

2019-07-14

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Case series:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who use the Apatinib mesylate tablets, regardless of first use and indications, Apatinib mesylate tablets are prescribed by physicians in accordance with clinical practice.

Exclusion criteria

Exclusion criteria: Patients who have not been treated with Apatinib mesylate tablets.

Design outcomes

Primary

Measure	Time frame
adverse reaction;	—

Countries

China

Contacts

Public ContactHuohui Li

Cancer Hospital Chinese Academy of Medical Sciences

zlyyliguohui@163.com+86 010 87788573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026